Skip to content

4538.T

Fuso Pharmaceutical Industries,Ltd.

プライム · 医薬品 · 医薬品 · JP

JPY 2,272.00
−0.61%
Ask drillr

Year over year

Reported trailing growth

Revenue
+2.9%
EBITDA
EBIT
-36.1%
EPS
+161.2%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
-1.3%
EBITDA
EPS
+14.3%

Three-year CAGR

Revenue
+6.9%
EBITDA
+3.9%
EBIT
+6.2%
Net income
+7.8%
EPS
+8.8%
Free cash flow
-38.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026